ACS omega

Liraglutide and Dapagliflozin together change gut bacteria and metabolism to improve type 2 diabetes in mice

Updated

Abstract

Combination treatment with liraglutide and dapagliflozin resulted in significantly greater improvements in body weight, glucose tolerance, and insulin sensitivity compared to monotherapies.

  • The combination therapy restored pancreatic islet architecture and increased β-cell mass more effectively than individual treatments.
  • Metagenomic analysis indicated that the combination altered gut microbiota by reducing harmful bacteria and enhancing beneficial species.
  • Metabolomics revealed normalization of the diabetic plasma metabolome, affecting pathways related to tryptophan and branched-chain amino acid metabolism.
  • A significant correlation was found between specific gut bacteria and host metabolites, suggesting a functional interaction that may enhance therapeutic effects.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free